Navigation Links
Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Date:1/22/2013

SEATTLE, Jan. 22, 2013 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) is pleased to announce the January publication of a paper titled "Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T-cells", authored by Henle et al, J.Immunol. (2013), 190, 479-488.  This work, performed in the laboratory of Dr Keith Knutson at Mayo Clinic, describes the discovery of a novel HER-2/neu Class I epitope (p373-382) TapImmune has licensed from Mayo Clinic for the development of breast cancer vaccines.  The significance of this work is that this newly discovered antigen is a naturally occurring antigen processed by the proteasome and elicits peptide-specific T-cell responses.  This results in stronger binding to HLA-A2 and more efficient killing of HER-2/neu positive breast cancer cells by activated T-cells compared to the Class I epitope, p369-377 (E75) which was not naturally processed by the proteasome.

"These results provide an explanation of the molecular immunology behind our approach to HER-2/neu immunotherapy," said Mark Reddish Vice President of TapImmune Inc.  "These data describe how the HER-2/neu protein is processed by the proteasome to then be presented for immune recognition and killing.  By revealing the true identity of the immunodominant epitope responsible for class I mediated killing of HER-2/neu positive tumors, it is now possible to generate a true second generation vaccine that incorporates the correct target as it naturally appears on human tumors.  For nearly 20 years the immunology of this key protein has been clouded by contradictory observations, and these data finally provide an understanding of the 'natural target' displayed on human tumors. We expect to combine this immunodominant peptide with our broadly reactive helper peptides that are currently being tested in a phase I trial, to create a true second generation vaccine candidate."  TapImmune's approach to development of a vaccine to treat HER-2/neu breast cancer is described in a white paper that can read at our website (www.tapimmune.com).

About TapImmune Inc.
TapImmune Inc. is a vaccine technologies company specializing in the development of innovative gene based immunotherapeutics and vaccines in the areas of oncology and infectious disease.  The Company's lead product candidates, include vaccines designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system.  The Company is also developing TAP-based prophylactic vaccines commercially suitable for the prevention of infectious diseases and as Biodefense agents.  As a vaccine component, the gene based TAP technology has the potential to significantly improve the efficacy of both prophylactic and immunotherapeutic vaccines as it addresses a fundamental mechanism for T cell recognition and response.  Unlike other vaccine technologies that address only the initiation of immune responses, TAP expression also has the unique ability to enhance the effector function of mature killer T cells. This enhancement of effector function is potentially complementary to any/all vaccine approaches that are designed to enhance cellular responses.  The Company is developing cancer vaccines that combine the use of novel antigens together with its TAP expression technology.

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

CONTACT
Glynn Wilson , Ph.D.
Chairman & CEO
(206) 504-7280


'/>"/>
SOURCE TapImmune Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Report Details NCPA Efforts to Drive Greater Medication Adherence
2. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
3. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
4. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
5. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
6. Physician Details Problems with Medicare Approval Process for Power Wheelchairs
7. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
8. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
9. MAQUET Cardiovascular Announces U.S. Food and Drug Administration Panel Votes To Reclassify Intra-Aortic Balloon Pumps To A Class II Designation In Certain Indications
10. Barrack, Rodos & Bacine Files Class Action Lawsuit Against St. Jude Medical, Inc.
11. Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2019)... ... September 13, 2019 , ... ... in Montreal provided a plethora of breakthrough research studies including several cancer ... to detect breast cancer, response prediction of cancer immunotherapies and whole body, ...
(Date:9/14/2019)... ... 2019 , ... CME4Life, a leading provider of physician assistant ... at a world record “Longest Medical Lecture” on November 16, 2019. The lecture ... CME credits in 30 consecutive hours. ?The conference will take place at The ...
(Date:9/11/2019)... ... September 12, 2019 , ... Understanding the Drug Supply ... Webinar, Thursday, Sept. 26, 2019, 1:30-3:00 p.m. EDT, https://www.fdanews.com/understanding-the-dscsa , Need ... the company clear on nuances of the guidelines regulating the drug supply chain? ...
Breaking Medicine Technology:
(Date:9/11/2019)... ... September 11, 2019 , ... Ahipoki is excited to announce a new vegan ... to vegans, vegetarians, pescatarians and poke bowl fans alike. Ahimi is made of ... its meaty texture similar to tuna, Ahipoki customers will now have a ...
(Date:9/11/2019)... ... September 10, 2019 , ... Women’s Excellence is excited to announce ... at 32686 Woodward Ave, Suite 103, Royal Oak, MI 48073 in the heart of ... offers comprehensive women’s health services in a contemporary, spa-like atmosphere. We are thrilled ...
(Date:9/11/2019)... ... September 10, 2019 , ... Four Shriners for ... physicians have been recognized among the best doctors in the San Gabriel Valley ... Robert H. Cho, M.D. – Chief of Staff, scoliosis, spinal deformity ...
(Date:9/11/2019)... (PRWEB) , ... September 10, 2019 , ... ... provide critical support to the most vulnerable communities impacted by Hurricane Dorian. ... in South Carolina, the Episcopal Diocese of Georgia, and the Episcopal Farmworker Ministry, ...
(Date:9/9/2019)... HERNDON, Va. (PRWEB) , ... September 09, 2019 ... ... North America, today announced that IP Access International will integrate the iDirect iQ ... terminal, a portable and hybrid communications solution for first responders. The iQ 200 ...
Breaking Medicine News(10 mins):